HUTCHMED DRC

Price & Volume

Track all markets on TradingView

Stats

See more
52W Range
$11.50-$21.92
Market Cap
$2.6B
Shares Short
360,596

Financials

See more
Revenue (12 Mos)
$630.2M
Revenue Growth (YoY)
6.4%
Gross Profit (12 Mos)
$69.2M
Diluted EPS
$0.20

News

See more

Yahoo Finance • last month

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

Yahoo Finance • last month

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

Yahoo Finance • 10 months ago

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

Yahoo Finance • last year

HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms

About

CEO
Dr. Wei-Guo Su B.Sc., Ph.D.
CFO
Mr. Chig Fung Cheng BEc, CA
Address
Cheung Kong Center, Hong Kong, Hong Kong
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Full-Time Employees
1,811